RosVivo Therapeutics, Inc. signed a Material Transfer Agreement (MTA) for first-in-class diabetes treatment with Eli Lilly and Company
PR94629
SEOUL, South Korea, Feb. 22, 2022 /PRNewswire=KYODO JBN/ --
- RSVI-301, a new drug candidate adopting miRNA technology, enters the
technology export process.
RosVivo Therapeutics, Inc. (hereinafter referred to as "RosVivo") announced
that it has signed a Material Transfer Agreement (MTA) with one of the largest
global pharmaceutical companies Eli Lilly and Company (hereinafter referred to
as "Eli Lilly") for commercial development of diabetes and obesity treatments.
Material Transfer Agreement indicates a contract to deliver candidate
substances to the other company for verifying the efficacy of the drug
substances through experiments and sharing the research (experimental) results.
MTA is considered as an initial step of processes towards technology export and
license-out.
Conducting considerable experiments with animal models in previous, RosVivo has
collected strong and compelling data for RSVI-301's efficacy compared to GLP-1
receptor agonist. GLP-1 receptor agonist is currently known as a game-changer
to treat diabetes and obesity in the market. Eli Lilly will review and
acknowledge the animal experiment data and ensure the potential of RSVI-301
through this MTA.
RosVivo's RSVI-301 pipeline is the world's first in class new drug candidate
that can fundamentally treat diabetes by restoring the function of beta cells
that secrete insulin, the cause of diabetes, and at the same time lowering
insulin resistance. Currently, diabetes is not fundamentally treated because
diabetes drugs only temporarily lower blood sugar. In addition, RSVI-301 is
considered an ideal next-generation new drug candidate for diabetes treatment
with fewer side effects as it shows excellent therapeutic effects on obesity,
fatty liver and digestive gastrointestinal disorders in animal testing.
An official from the RosVivo said, "The fact that it went through CDA with Eli
Lilly, a global diabetes treatment company, proved the possibility of new drug
candidates and we are also confident in licensing out." He also mentioned as,
"In addition to Eli Lilly, the RosVivo received attention for its candidates
from other global pharmaceutical companies."
SOURCE:RosVivo Therapeutics, Inc.
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=415581
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。